机构:[1]Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern medical University, Guangzhou, Guangdong, People’s Republic of China[2]Department of Hepatobiliary Surgery, The Affiliated Hospital of Luzhou Medical College, Luzhou, Sichuan, People’s Republic of China[3]Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China浙江大学医学院附属第一医院[4]Department of Oncology, Guangzhou Chest Hospital, Guangzhou, Guangdong, People’s Republic of China
To investigate the expression and role of Cathepsin L (CTSL) in Hepatocellular carcinoma (HCC) tissue and cell line (MHCC-97H), and to evaluate the clinical and prognostic significance of CTSL protein in patients with HCC.
The expression of CTSL was examined in HCC tissue and MHCC-97H cells by Western-blotting, Real-time PCR and immunohistochemical staining. Cell growth curve assay and colony formation assay were used to verify the effect of CTSL on the proliferation and tumor progression ability of MHCC-97H cells. Tumor formation assay in nude mice was used to analyze the effect of CTSL on the tumorigenicity of MHCC-97H cells.
The status of CTSL protein in carcinoma tissues is much higher than that in paracarcinoma tissues. The overall survival of the patients with high CTSL expression was significantly shorter than the low CTSL expression group. high CTSL expression was significantly correlated with advanced clinical staging, histological grade and tumor recurrence. In vitro experiments demonstrated that over-expression of CTSL in MHCC-97H cells promoted cell proliferation and tumor progression ability. Down-regulation of CTSL showed the opposite effects. Over-expression of CTSL increase the tumorigenicity of MHCC-97H cells by in vivo experiments. Moreover, multivariate analysis suggested that CTSL expression might be an independent prognostic indicator for the survival of HCC patients after curative surgery.
CTSL might involve in the development and progression of HCC as a oncogene, and thereby may be a valuable prognostic marker for HCC patients.
基金:
National Natural Science Foundation of China (Grant No. 81001212), The Science and Technology Foundation of
Zhejiang Province (Grant No. 2012C33011), Foundation of State Key Laboratory of Oncology in South China (Grant No. HN2011-03), Zhejiang Provincial Chinese
Medicine Research Foundation (Grant No. 2010ZB062, 2011ZQ012), Foundation of Zhejiang Provincial Educational Committee (Grant No. Y201019175), and
Natural Science Foundation of Guangdong (Grant No. s2012010008209)
第一作者机构:[1]Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern medical University, Guangzhou, Guangdong, People’s Republic of China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Ruan Jian,Zheng Hang,Fu Wenguang,et al.Increased expression of cathepsin L: a novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients.[J].PloS one.2014,9(11):e112136.doi:10.1371/journal.pone.0112136.
APA:
Ruan Jian,Zheng Hang,Fu Wenguang,Zhao Peng,Su Ning&Luo Rongcheng.(2014).Increased expression of cathepsin L: a novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients..PloS one,9,(11)
MLA:
Ruan Jian,et al."Increased expression of cathepsin L: a novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients.".PloS one 9..11(2014):e112136